PaperHemostasis activation in patients with liver cirrhosis
References (18)
- et al.
Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis
Thromb Res
(1991) - et al.
α2-antiplasmin and disseminated intravascular coagulation in liver cirrhosis
Thromb Res
(1985) - et al.
Quantitative determination of human protein C
Thromb Res
(1988) - et al.
Immunological and functional determination of the protease inhibitors, protein C and antithrombin III, in liver cirrhosis and in neoplasia
Thromb Res
(1988) Disseminated intravascular coagulation in Cirrhosis
Hepatology
(1989)- et al.
The natural history of Laennec's cirrhosis of the liver: an analysis of 386 cases
Medicine
(1942) - et al.
Haemostatic problems in liver disease
Gut
(1986) - et al.
The α2-plasmin inhibitor levels in liver disease
Clin Chim Acta
(1978) - et al.
Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis
Brit J Haematol
(1982)
Cited by (42)
Predictors of cancer in patients with acute pulmonary embolism
2023, Thrombosis ResearchThe portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
2022, Journal of Thrombosis and HaemostasisCitation Excerpt :We detected no local increase in NET markers in portal nor in hepatic plasma, suggesting there is not (at least) a direct link between local inflammation and NETs in portal hypertension in cirrhotic patients. TAT, PAP, and D‐dimers, which are markers of activation of coagulation and fibrinolysis, have been shown to be elevated in patients with cirrhosis compared with healthy controls.28 Although our results indicate elevated levels of these markers in portal plasma compared with hepatic and peripheral plasma, on careful inspection, levels of these markers are clearly the lowest in the HV.
Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development
2009, Journal of HepatologyCitation Excerpt :In a previous study, TRFs were found to be independently associated with the extent of fibrosis in patients with chronic hepatitis [10]. The results obtained in the present study confirm several earlier reports showing that haemostatic tests could be of great practical value in the assessment of hepatocyte function in liver disease [6,13,27,40,41]. Not surprisingly, our study showed that the reduction in the level of antithrombotic proteins is strongly related to the severity of liver cirrhosis according to the MELD scoring system.
The use of D-dimer in specific clinical conditions: A narrative review
2009, European Journal of Internal MedicineCitation Excerpt :More co-morbidity can also be expected in patients admitted to the hospital (inpatients), providing a sample with elevated D-dimer levels. Factors that can contribute to a higher level of D-dimer are extensive inflammation, malignancy, surgery and liver disease [32–35]. Hospitalized patients are also at higher risk for developing VTE with an increased mortality rate [36].
Hypercoagulation in Liver Disease
2009, Clinics in Liver DiseaseCitation Excerpt :Congenital genetic defects in protein C, protein S, antithrombin III, and prothrombin production are well-known causes of inappropriate thrombosis. It has been documented that in patients with cirrhosis, serum levels of all of these proteins can be low because of decreased production.1,2 The procoagulant factors prothrombin, V, VII, IX, X, and XI13 are also commonly low in patients who have liver disease.
Hypercoagulation and thrombophilia in liver disease
2008, Journal of Thrombosis and Haemostasis